by a mutation in the CYP4V2 gene that causes metabolic enzyme dysfunction wherein yellow-white crystalline lipid deposits form in the retina and cornea, causing the retinal pigment epithelium to degenerate. Resultant symptoms include night...
of Flow Cleanrooms and Supply and Technical Air Products. Today, Modular Devices Cleanrooms serves as a comprehensive platform, offering pre-built cleanrooms for lease or purchase, along with custom modular solutions tailored to highly regulated...
the Company's therapeutics portfolio derived from its novel, proprietary X-E3L (Crosslinking E3 Labeller) technology platform which accelerates the discovery of first-in-class small molecule protein stabilising drugs targeting E3 ligases. Dr...
Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe®, a benchtop, continuous flow RNA in vitro transcription (IVT) and...
of Manchester. “Chemify is uniquely positioned to disrupt the industry through its AI, digital chemistry and robotics platform that will not only optimize and expedite the discovery of novel molecules, but accelerate the availability of life-saving...
Board of Directors and Partner, Monograph Capital. "We started Ouro with an intention of building a discovery platform to unlock immune reset therapeutics, and we have been excited to accelerate the company's development by bringing in OM336, which...
In founding his skincare company, Murad, in 1989, Dr. Murad, MD, FAAD, brought to the world his groundbreaking skincare formulas that produce measurable results without cosmetic surgery. His more recent efforts have focused on Modern Wellness,...
In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...
of certain items in NLS's extraordinary general meeting on January 7, 2025. As previously detailed in NLS's Report on Form 6-K submitted to the Securities and Exchange Commission on December 4, 2024, this agreement involved no warrants and was...
Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor for rare and common cardiovascular diseases. For more information, please visit https://cardurion.com.
the growing demands of the cell and gene therapy industry." PBS' Vertical-Wheel® bioreactors have demonstrated superior performance for production of therapeutic cells designed as regenerative medicines for conditions like diabetes, cancer, and...
co-founder, Dr. Ahna Skop, who discovered that these structures contain RNA and active translation – a finding that transformed our understanding of cellular communication and cancer detection. "MBRs are produced every cell division and they are...
and correction of bone. The Revolution EPS and Revolution Trauma products are available now for all current Fusion and former Metalogix qualified distributors in their respective markets throughout the United States. This groundbreaking technology...
Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, please visit, www.spyre.com.
and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice®platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in...
stapling with its 90° articulation capability, providing surgeons with the maneuverability and precision necessary to perform effective stapling even in the most confined spaces. This innovation potentially reduces the need for multiple stapler...
first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United States. Eden believes a healthier...
statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the...
said Dr. Stephen Weeks, VP of Structural Biology at Orthogon Therapeutics. “This achievement highlights our platform’s ability to target previously undruggable viral proteins.” This breakthrough coincides with Orthogon’s creation of a pioneering...
and better outcomes for patients worldwide. "This collaboration marks a significant step forward in our mission to transform lupus nephritis treatment," said Dr. Alon Yaar, CEO of LIVEKIDNEY.BIO. "By joining forces with Isotopia, we are confident...
